Index Predicts 10-, 14-Year Mortality in Older Adults

This article originally appeared here.
Share this content:
Index Predicts 10-, 14-Year Mortality in Older Adults
Index Predicts 10-, 14-Year Mortality in Older Adults

MONDAY, March 6, 2017 (HealthDay News) -- An 11-factor index predicts 10- and 14-year mortality with excellent calibration and discrimination among community-dwelling U.S. adults aged ≥65 years, according to a study published online Feb. 21 in the Journal of the American Geriatrics Society.

Mara A. Schonberg, M.D., M.P.H., from Beth Israel Deaconess Medical Center in Boston, and colleagues examined the performance of an index in predicting 10- and 14-year mortality for community-dwelling adults aged ≥65 years from the 1997 to 2000 National Health Interview Surveys. Data were included for 16,063 and 8,027 respondents from the original development and validation cohorts. Risk scores were calculated based on the presence or absence of 11 factors that make up the index. Model calibration was examined by computing the 10- and 14-year mortality estimates with the Kaplan Meier method.

The researchers found that 14-year mortality was 23 percent for participants with risk scores of 0 to 4, compared with 89 percent for those with risk score of 13+. In both cohorts, the C-index was 0.73 and 0.72 for predicting 10- and 14-year mortality, respectively. Overall, 18.4 and 60.2 percent of those aged 65 to 74 years and ≥75 years had more than 50 percent risk of mortality in 10 years.

"Information on long-term prognosis is needed to help clinicians and older adults make more informed person-centered medical decisions and to help older adults plan for the future," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »